相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Adverse effects during treatment with renin-angiotensin-aldosterone system inhibitors; should we stay or should we stop?
Silvia J. Leon et al.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2023)
Patiromer utilization in patients with advanced chronic kidney disease under nephrology care in Germany
Roberto Pecoits-Filho et al.
CLINICAL KIDNEY JOURNAL (2023)
Stopping renin-angiotensin system inhibitors after hyperkalemia and risk of adverse outcomes
Yang Xu et al.
AMERICAN HEART JOURNAL (2022)
Hyperkalemia-Related Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in CKD: A Population-Based Cohort Study
Silvia J. Leon et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2022)
Can Novel Potassium Binders Liberate People with Chronic Kidney Disease from the Low-Potassium Diet? A Cautionary Tale
David E. St-Jules et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2022)
Stopping versus continuing renin-angiotensin-system inhibitors after acute kidney injury and adverse clinical outcomes: an observational study from routine care data
Roemer J. Janse et al.
CLINICAL KIDNEY JOURNAL (2022)
Assessment of Patiromer Monotherapy for Hyperkalemia in an Acute Care Setting
Katherine E. Di Palo et al.
JAMA NETWORK OPEN (2022)
Cost-Effectiveness of Treating Patients with Chronic Kidney Disease and Prior Hyperkalemia with Renin-Angiotensin-Aldosterone System Inhibitor and Patiromer: A Swiss Public Healthcare Perspective
Barbara Fischer et al.
ADVANCES IN THERAPY (2022)
Compounding Benefits of Cholesterol-Lowering Therapy for the Reduction of Major Cardiovascular Events: Systematic Review and Meta-Analysis
Nelson Wang et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2022)
Risk of Hospitalization for Heart Failure in Patients With Hyperkalemia Treated With Sodium Zirconium Cyclosilicate Versus Patiromer
Min Zhuo et al.
JOURNAL OF CARDIAC FAILURE (2022)
Comparative efficacy of patiromer and sodium polystyrene sulfonate on potassium levels in chronic haemodialysis patients: a randomized crossover trial
David A. Jaques et al.
CLINICAL KIDNEY JOURNAL (2022)
Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial
Javed Butler et al.
EUROPEAN HEART JOURNAL (2022)
Potassium binders for patients with heart failure? The real enlightenment of the DIAMOND trial
Milton Packer
EUROPEAN HEART JOURNAL (2022)
Efficacy and safety of potassium binders in the treatment of patients with chronic kidney disease and hyperkalemia
Lingqiu Dong et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2022)
Clinical Efficacy, Safety, Tolerability, and Real-World Data of Patiromer for the Treatment of Hyperkalemia
Gates Colbert et al.
DRUG HEALTHCARE AND PATIENT SAFETY (2022)
The Cost Effectiveness of Patiromer for the Treatment of Hyperkalaemia in Patients with Chronic Kidney Disease with and without Heart Failure in Ireland
Thomas Ward et al.
PHARMACOECONOMICS-OPEN (2022)
Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)
Ian H. de Boer et al.
KIDNEY INTERNATIONAL (2022)
Real-world evaluation of patiromer utilization and its effects on serum potassium in veterans with end stage kidney disease
Derek Pinnell et al.
MEDICINE (2022)
Safety and Tolerability of the Potassium Binder Patiromer From a Global Pharmacovigilance Database Collected Over 4 Years Compared with Data from the Clinical Trial Program
Patrick Rossignol et al.
DRUGS-REAL WORLD OUTCOMES (2021)
Effects and Safety of a Novel Oral Potassium-Lowering Drug-Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia: a Systematic Review and Meta-Analysis
Yaru Zhang et al.
CARDIOVASCULAR DRUGS AND THERAPY (2021)
Adverse gastrointestinal events with sodium polystyrene sulphonate and calcium polystyrene sulphonate use in dialysis patients: a nationwide registry study
Joao Pedro Ferreira et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2021)
Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care
Marco Trevisan et al.
EUROPEAN JOURNAL OF HEART FAILURE (2021)
Initiation of sodium polystyrene sulphonate and the risk of gastrointestinal adverse events in advanced chronic kidney disease: a nationwide study
Paola Laureati et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2020)
Patiromer for Treatment of Hyperkalemia in the Emergency Department: A Pilot Study
Zubaid Rafique et al.
ACADEMIC EMERGENCY MEDICINE (2020)
Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Catherine M. Clase et al.
KIDNEY INTERNATIONAL (2020)
Potassium Binders for Hyperkalemia in Chronic Kidney Disease-Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis
Biff F. Palmer
MAYO CLINIC PROCEEDINGS (2020)
Emergency Potassium Normalization Treatment Including Sodium Zirconium Cyclosilicate: A Phase II, Randomized, Double-blind, Placebo-controlled Study (ENERGIZE)
W. Frank Peacock et al.
ACADEMIC EMERGENCY MEDICINE (2020)
Stopping renin-angiotensin system blockers after acute kidney injury and risk of adverse outcomes: parallel population-based cohort studies in English and Swedish routine care
Patrick Bidulka et al.
BMC MEDICINE (2020)
Plant-based diets to manage the risks and complications of chronic kidney disease
Juan J. Carrero et al.
NATURE REVIEWS NEPHROLOGY (2020)
Estimating the Lifetime Benefits of Treatments for Heart Failure
Joao Pedro Ferreira et al.
JACC-HEART FAILURE (2020)
Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia A 12-Month Phase 3 Study
Bruce S. Spinowitz et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2019)
Risk of Hospitalization for Serious Adverse Gastrointestinal Events Associated With Sodium Polystyrene Sulfonate Use in Patients of Advanced Age
J. Ariana Noel et al.
JAMA INTERNAL MEDICINE (2019)
Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists
Marco Trevisan et al.
EUROPEAN JOURNAL OF HEART FAILURE (2018)
The tolerability and safety profile of patiromer: a novel polymer-based potassium binder for the treatment of hyperkalemia
Bertram Pitt et al.
EXPERT OPINION ON DRUG SAFETY (2018)
Gastrointestinal symptoms in patients receiving dialysis: A systematic review
Jordan Zuvela et al.
NEPHROLOGY (2018)
Randomized Clinical Trial of Sodium Polystyrene Sulfonate for the Treatment of Mild Hyperkalemia in CKD
Laurence Lepage et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease The AMETHYST-DN Randomized Clinical Trial
George L. Bakris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia
David A. Bushinsky et al.
KIDNEY INTERNATIONAL (2015)
Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors
Matthew R. Weir et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Sodium Zirconium Cyclosilicate in Hyperkalemia
David K. Packham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Potassium-Binding Resins Associations with Serum Chemistries and interdialytic weight Gain in Hemodialysis Patients
Michel Jadoul et al.
AMERICAN JOURNAL OF NEPHROLOGY (2014)
Effect of Sodium Zirconium Cyclosilicate on Potassium Lowering for 28 Days Among Outpatients With Hyperkalemia The HARMONIZE Randomized Clinical Trial
Mikhail Kosiborod et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Association of Prescription of Oral Sodium Polystyrene Sulfonate With Sorbitol in an Inpatient Setting With Colonic Necrosis: A Retrospective Cohort Study
Maura A. Watson et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2012)